DRRX Plunges On Psoriasis Trial Data, INCY Fails GRAVITAS-301 Test, AGRX Abuzz

(RTTNews) - Today's Daily Dose brings you news about Agile Therapeutics' strengthened commercial leadership team; DURECT's decision to discontinue the development of DUR-928 in mild to moderate plaque psoriasis; Novan's disappointing molluscum contagiosum trial results; Incyte's acute graft-versus-host disease trial results and Innate Pharma's regulatory catalyst that drove the stock to a new 52-week high.

Read ona?¦

Agile Therapeutics Inc. (AGRX) has appointed Kimberly Whelan as Vice President of Market Access and filled two additional positions to further strengthen its finance and marketing capabilities. Charles Grass, CMA, has been named Senior Director, Finance and Matthew Riley has been named Product Manager.

The Company's lead product candidate, Twirla, awaits the FDA decision on February 16, 2020.

AGRX closed Thursday's trading at $2.97, up 18.80%.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »